PDF(Pubmed)
Abstract：
Lung cancer is one of the most common malignancies worldwide. Since the global outbreak of the coronavirus disease 2019 (COVID-19) pandemic in 2020, the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on lung cancer has been extensively studied. Despite reports about SARS-CoV-2 infection inducing a significant increase in the number of medical visits for patients with cancer, the virus has also been reported to produce some unknown benefits. The present study reports the case of a patient with lung cancer whose tumor lesion was reduced in size after SARS-CoV-2 infection even though the therapeutic regimen remained unchanged. Although the mechanism involved is not yet understood, this case supports the novel idea of applying SARS-CoV-2 in oncolytic virotherapy.
摘要：
肺癌是世界范围内最常见的恶性肿瘤之一。自2020年冠状病毒病2019（COVID-19）大流行全球爆发以来，严重急性呼吸道综合症冠状病毒2（SARS-CoV-2）对肺癌的影响已得到广泛研究。尽管有报道称SARS-CoV-2感染导致癌症患者就诊次数显着增加，据报道，该病毒还产生了一些未知的益处。本研究报告了一例肺癌患者，尽管治疗方案保持不变，但SARS-CoV-2感染后肿瘤病灶缩小。尽管所涉及的机制尚不清楚，该病例支持在溶瘤病毒治疗中应用SARS-CoV-2的新想法。
